ArticleJournal of molecular histology2025
Role of indoleamine 2,3-Dioxygenase 1 in modulating the malignant biological behavior of cervical cancer cells through the Tryptophan-Kynurenine pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The microbiota-host metabolic axis in cervical cancer: from homeostatic disruption to mechanisms of therapy resistance.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe aim of this study is to evaluate the influence of altered expression of indoleamine 2,3-dioxygenase 1 (IDO1) on key enzymes and metabolites within the tryptophan-kynurenine pathway, as well as to assess the resulting effects on the malignant biological behavior of cervical cancer cells, including proliferation, invasion and migration.
methodsIDO1 expression was assessed in cervical cancer and normal cervical tissues via immunohistochemistry and western blot (WB) analysis. Four human cervical cancer cell lines (HeLa, C33A, SiHa, CaSki) were cultured, and HeLa and SiHa cells-characterized by elevated IDO1 expression-were selected for further experimentation. IDO1 was silenced using RNA interference techniques. Quantitative real-time polymerase chain reaction and WB were used to detect the messenger RNA and protein expression levels of IDO2, tryptophan 2,3-dioxygenase (TDO), kynurenine 3-monooxygenase (KMO), and aryl hydrocarbon receptor (AhR). Targeted metabolomics analysis based on liquid chromatography-tandem mass spectrometry was conducted to quantify tryptophan, N-formylkynurenine (NFK), and L-kynurenine (L-KYN) in cell culture supernatants. Cell proliferation, apoptosis, and migratory capacity were evaluated via flow cytometry and scratch assays.
resultsIDO1 expression was significantly elevated in cervical cancer tissues compared to normal cervical tissues, with the highest levels observed in samples positive for human papillomavirus types 16 or 18. Silencing of IDO1 in cervical cancer cells resulted in downregulation of IDO2, TDO, KMO, and AHR expression. Correspondingly, reduced metabolic activity in the tryptophan-kynurenine pathway was observed, evidenced by decreased levels of NFK and L-KYN. These molecular alterations were associated with G1 phase cell cycle arrest, diminished cellular proliferation, migration and invasion, and increased apoptotic activity.
conclusionIDO1 mediates the malignant biological behavior of cervical cancer cells through the tryptophan-kynurenine pathway, suggesting its potential as a therapeutic target in cervical malignancies.
Indexed as
Identifiers
40844661What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.